Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33384668

about

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity Management of the adverse effects of lenalidomide in multiple myeloma.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.Initial testing of lenalidomide by the pediatric preclinical testing program Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo Approach to chemotherapy-associated thrombosis.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspective Lenalidomide: a synthetic compound with an evolving role in cancer management.The potential of immunomodulatory drugs in the treatment of solid tumors.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents.Current strategies for treatment of relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Current therapeutic strategies for multiple myeloma.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.An update on the use of lenalidomide for the treatment of multiple myeloma.Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.The safety of daratumumab for the treatment of multiple myeloma.

P2860

Q26771331-ADE79C73-3D88-45DE-BA3D-AC4ED039CF5B Q33394632-171AFA49-92D4-419A-A74E-CD6BB2A4EFC7 Q33398044-D611DA80-FB75-4B38-A099-16072E8EFB74 Q33399416-1574ECA3-10EA-4431-AEB0-DEED9866DCE0 Q33403183-22D0E405-9DE2-4CA9-8198-707E6E96D74E Q33404007-8FA55FE9-044B-4DCC-98E4-7F9DCEF058F0 Q33409681-FFF77744-4F59-4F5A-8045-89C44389930D Q33412636-90249E1A-BC86-427B-A552-7DDBB0A8DBB8 Q33414647-C5FEB502-02C6-4BE5-B6CD-DD5AC8ACBEF4 Q33632270-92FC4010-C21F-45A3-A7EB-D35AF6C75E60 Q33973877-648EAAB4-37A7-46D6-AED9-7BE874E49221 Q34008578-9BEA0E60-9652-456C-B34A-FA1B496BA6F9 Q34166574-ED8E16DE-E044-4A0A-8307-6E0584FCB32E Q34213649-E6F62DFE-3EE6-46AE-9AFA-BE3C96C219FA Q34549211-64455A8A-A09C-4C3E-849E-D915B9258637 Q34719436-1B05B4A8-8728-48F6-A904-2CEB3EE58861 Q35608564-6412DDC3-AE34-4DFA-9FBE-5FBEF75FD833 Q35861457-073215FE-98B1-4483-8C35-A88817C39184 Q35895152-874A2718-6C52-4E1D-A619-3C528E5C1B80 Q36070261-A9001C79-8405-4B65-8961-987360109991 Q36162685-B1447658-7324-4ACC-9445-A535232B0459 Q36304793-8F5D24AE-7B45-4501-B403-5BD43A4804C0 Q36806619-E66AA755-F9F6-4239-AAEB-D576CEE941DF Q37076421-CE5BFE8E-E028-4B0A-BAEF-D2EAACC4639A Q37677935-6064262E-8A40-46AB-8783-28812D41FFAA Q37791617-238D2533-3B74-4BDA-A5A7-10E796740399 Q37797475-F8B09839-53BF-4EB3-AE3C-9AC3878F99D3 Q37831402-2DC577F4-49D2-43A9-A5F8-267CF07E1409 Q37835695-8C37C1C6-5B3F-43E8-8736-55CFA8E52AC3 Q37862262-0998D130-C5C3-49EA-ACEA-94115A236750 Q38025158-65AE0186-2479-4594-864A-35A173C23589 Q38162876-823B6941-4EE6-43F7-B51E-EC3F33C33DDB Q38182683-12537496-BB0F-41FC-8208-C6030483194C Q38261677-88F13963-D5EC-4E06-AC14-D46C39671277 Q38271032-6AEE0892-F9E0-4F3C-842B-21FF65568A63 Q38412189-1D0DC18E-F45E-409A-9EFF-C6FF3F592B16 Q38530066-B372A157-D44A-4C7B-A2DF-76F34BDE7119 Q38545607-5CDE5105-00B5-4111-890D-E568820A9DB6 Q38714708-7A5D7C66-A3A6-4DA3-A4F0-24987C830CD9 Q38793959-2A861A0E-E9B3-41B2-90B4-0B9417704AF6

P2860

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33384668

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and efficacy of single- ...... d refractory multiple myeloma.

@ast

Safety and efficacy of single- ...... d refractory multiple myeloma.

@en

type

label

Safety and efficacy of single- ...... d refractory multiple myeloma.

@ast

Safety and efficacy of single- ...... d refractory multiple myeloma.

@en

prefLabel

Safety and efficacy of single- ...... d refractory multiple myeloma.

@ast

Safety and efficacy of single- ...... d refractory multiple myeloma.

@en

P1433

Q33384668-56DBB84D-1C43-4FA0-B8F1-F5EB5A27132E

P1476

Q33384668-98F3D87E-253E-44E8-854E-E5DECD45DA01

P2093

Q33384668-212A1911-6D23-439E-A89C-897B8E0E7619

Q33384668-2CA2BFBB-38C0-41A9-975C-F3FD6098615F

Q33384668-3176565D-6690-454C-BB63-A1726C59B1B1

Q33384668-38CC793F-C88E-43B0-955D-BD41328A988D

Q33384668-6E7AE3F0-24FA-40BF-B3DD-5269506D421F

Q33384668-71ADEFDA-2356-4A03-B40F-E3AB12BB01B1

Q33384668-88E392D3-980B-46D7-93A4-64FB48C1598F

Q33384668-9D87AE7C-9737-4F52-8CF1-53E9A4CD5913

Q33384668-A359B7F1-16D2-4A76-BB73-FEC0D82D77E1

Q33384668-A438CA5C-9836-40A0-AD9E-0AEE6F6BCA6E

P304

Q33384668-0E16E628-A233-4C64-B695-7A4A5ED27246

P31

Q33384668-D3DE1420-B33B-4AC4-B6DA-51488B428249

P356

Q33384668-6616C79A-D7CA-4E7D-9FB3-25A1E2A2E682

P407

Q33384668-CDD6E6B0-AE5F-4190-8B98-EF9A2551BF2F

P433

Q33384668-7C47A9DD-70A9-48E0-AB23-C0893177EA36

P478

Q33384668-13BC2942-B160-4408-A189-05A47C5647D7

P50

Q33384668-99442FDE-3FC5-400F-BE91-4F6F76A47700

Q33384668-A2D0397E-2DAF-42B0-98F9-56E14AD8C36E

P577

Q33384668-AD7AB5EE-8664-428A-929C-17DCC547E2E5

P698

Q33384668-33F3487C-785C-46A4-8E5D-69727256E44E

P356

BLOOD-2008-12-196238

P1433

P1476

Safety and efficacy of single- ...... d refractory multiple myeloma.

@en

P2093

Ashraf Z Badros

http://www.w3.org/2001/XMLSchema#string

David Irwin

http://www.w3.org/2001/XMLSchema#string

James Berenson

http://www.w3.org/2001/XMLSchema#string

Jerome Zeldis

http://www.w3.org/2001/XMLSchema#string

Laurie Kenvin

http://www.w3.org/2001/XMLSchema#string

Marta Olesnyckyj

http://www.w3.org/2001/XMLSchema#string

Mohamad Hussein

http://www.w3.org/2001/XMLSchema#string

Robert Knight

http://www.w3.org/2001/XMLSchema#string

Robert Vescio

http://www.w3.org/2001/XMLSchema#string

Seema Singhal

http://www.w3.org/2001/XMLSchema#string

P304

772-778

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-12-196238

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19471019

http://www.w3.org/2001/XMLSchema#string